Mucolipidosis type II Advocacy Hub | UniteRare

At a Glance

Live from database

Regulatory Watchboard

10 events

Jun 2026Evaluation of the Safety and Preliminary Efficacy of Neuroinduced Mesenchymal Stem Cells and Exosome Therapy in Patients With Spinocerebellar Palsy

Biocells Medical — PHASE1, PHASE2

TrialNOT YET RECRUITING

Mar 2026A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

Alliance for Clinical Trials in Oncology — PHASE2

TrialNOT YET RECRUITING

Mar 2026Evaluating Safety, Tolerability, and Efficacy of Autologous MitoCell Transplantation in Subjects With Idiopathic Parkinson's Disease

Taiwan Mitochondrion Applied Technology Co., Ltd. — PHASE1

TrialNOT YET RECRUITING

Feb 2026Study on the Safety and Efficacy of Intratympanic Injection of Small Extracellular Vesicles Derived From Mesenchymal Stem Cells in Severe and Profound Sudden Sensorineural Hearing Loss

The Affiliated Hospital of Qingdao University — PHASE1, PHASE2

TrialNOT YET RECRUITING

Feb 2026GYNORYLAQ™-VLINIVAL™: Ψ-Guided Personalized Neoantigen Peptide Vaccine for High-Risk Endometrial Cancer

Biogenea Pharmaceuticals Ltd. — EARLY_PHASE1

TrialENROLLING BY INVITATION

Dec 2025Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma

Shanghai JMT-Bio Inc. — PHASE1, PHASE2

TrialRECRUITING

Sep 2025Next Generation T-cell Vaccine Against Coronavirus Disease (COVID-19)

Gylden Pharma Ltd — PHASE1, PHASE2

TrialNOT YET RECRUITING

Mar 2025Dose Escalation of Allogeneic Adipose Derived Stroma/Stem Cells for the Treatment of Crohn's Fistula

University Hospital, Toulouse — PHASE1, PHASE2

TrialRECRUITING

Nov 2024Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors

Washington University School of Medicine — PHASE1

TrialRECRUITING

Apr 2024Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances

M.D. Anderson Cancer Center — PHASE1, PHASE2

TrialRECRUITING

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

FINANCIAL LANDSCAPE SUMMARY

Total programs

No financial assistance programs currently listed for Mucolipidosis type II.
Check the disease page for updates →

Clinical Trial Landscape

No active clinical trials currently recruiting for Mucolipidosis type II.
Search all trials →

Search clinical trials for Mucolipidosis type II →

Recent News & Research

No recent news articles indexed yet for Mucolipidosis type II.
Search PubMed for Mucolipidosis type II →

Browse all Mucolipidosis type II news →

Specialist Network

Top 6 by expertise

Paul Orchard, MD, MD

University of Minnesota Medical Center

📍 MINNEAPOLIS, MN

Score 3715 trials

Hope S. Rugo, MD, MD

University of California, San Francisco

📍 SAN FRANCISCO, CA

Score 325 trials

Scott M Norberg, D.O., D.O

National Cancer Institute (NCI)

📍 PHILADELPHIA, PA

Score 104 trials

Steven A Rosenberg, M.D.

National Cancer Institute (NCI)

Score 819 trials

Sara Cathey, MD

Greenwood Genetic Center

Score 51 trial

Anish Thomas, M.D.

National Cancer Institute (NCI)

Score 57 trials

View all Mucolipidosis type II specialists →

Quick Actions

📄

View Disease Page

Full profile, treatments, community

🔬

Search Clinical Trials

Find recruiting studies now

🩺

Find Specialists

Ranked by expertise & trials

💰

Financial Assistance

Copay cards, PAPs, grants

📰